Endoscopic Hemostasis Devices Market: as more than 240,000 gastrointestinal bleeding occurrences annually in the United States drive procedure urgency dynamics at emergency gastroenterology services, Boston Scientific Resolution Clip reaches 2.5 million patient lives at the top of an installed base and training network that creates intense GPO-anchored brand loyalty, so topical hemostatic spray systems including Medtronic Nexpowder address diffuse bleeding presentations that mechanical clip and thermal coagulation cannot effectively reach, and the aging global population projected to exceed 1.4 billion people over 60 by 2030 creates a structurally expanding high-risk GI bleeding patient population.

The global endoscopic hemostasis devices market size was USD 2.28 Billion in 2025 and is expected to register a revenue CAGR of 5.3% during the forecast period. Market revenue growth is driven by factors such as the structurally high annual burden of gastrointestinal bleeding events requiring emergency endoscopic intervention, the expanding market for topical hemostatic spray systems addressing diffuse bleeding presentations that mechanical clip and thermal coagulation cannot effectively reach, and as well as the aging global population creating a structurally expanding high-risk GI bleeding patient population requiring emergent hemostasis capability. The first driving factor is the high annual burden of gastrointestinal bleeding events requiring emergency endoscopic hemostasis intervention, with approximately 240,000 gastrointestinal bleeding occurrences annually in the United States from peptic ulcers, post-polypectomy bleeding, and diverticulosis, a global GI bleeding mortality rate of approximately 10% per published clinical data, and the American Society for Gastrointestinal Endoscopy positioning endoscopic hemostasis as the primary treatment modality for non-variceal upper GI bleeding with thermal coagulation, mechanical hemostasis clips, and topical hemostatic agents recommended as first-line interventions before surgical or radiological escalation. The second driving factor is the commercial maturation of topical hemostatic spray and powder systems including Medtronic Nexpowder FDA-cleared September 2022 and NEXTBIOMEDICAL Nexpowder-S MFDS-approved November 2024, expanding the hemostasis device market into diffuse bleeding presentations including post-ESD mucosal ooze, coagulopathic GI bleeding, and superficial bleeding vessel treatment where mechanical clipping or thermal coagulation is technically challenging and less effective. The third driving factor is the structurally expanding high-risk GI bleeding patient population generated by global demographic aging, with the WHO October 2024 report confirming that by 2030 one in six people globally will be over the age of 60, reaching 1.4 Billion people, and the over-80 population tripling to 426 Million by 2050, the demographic most susceptible to peptic ulcer disease, diverticular bleeding, and gastrointestinal malignancies requiring endoscopic hemostasis intervention. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way procedure urgency dynamics in emergency GI bleeding create intense brand loyalty anchored by GPO contract pricing that sustains per-device revenue without requiring active commercial selling at each procedure episode, which allows the hemostasis device categories with the largest installed base and training network advantages to maintain revenue concentration well above what competitive device specification alone would predict. Once a hospital endoscopy unit stocks Boston Scientific Resolution Clip as the standard hemostatic clip, the urgency of emergency upper GI bleeding presentations means the endoscopist reaches for whichever clip is on the shelf during the procedure, so switching hemostasis device brands requires retraining staff, rebuilding supply chain relationships, and running comparative cost analysis against existing GPO contract pricing, creating multi-year switching barriers that sustain per-unit revenue concentration in established device platforms. As a result, demand and revenue share are concentrating around the device platforms with the deepest GPO contract positions and the broadest physician training networks, and the forecast tilts toward these established platforms rather than new device entrants lacking equivalent procedure penetration. For instance, in July 2024, Medtronic launched an Advanced Energy Platform integrating artificial intelligence algorithms for optimal energy delivery during thermal hemostasis procedures, one of several commercial and regulatory events that reshaped the competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the structurally high and growing burden of gastrointestinal bleeding events that require emergency endoscopic hemostasis intervention, driven by the combination of a persistent peptic ulcer disease and diverticulosis prevalence base and a rapidly aging global population that carries proportionally higher GI bleeding risk from both benign and malignant GI pathology. GI bleeding drives hemostasis device demand because approximately 240,000 gastrointestinal bleeding occurrences take place in the United States each year from peptic ulcers, post-polypectomy bleeding, and diverticulosis per Boston Scientific product documentation, with a global GI bleeding mortality rate of approximately 10%, establishing emergency endoscopic hemostasis as a life-saving procedure with non-discretionary per-episode device demand that does not respond to cost-containment pressure the way elective device categories do. The World Health Organization October 2024 report confirmed that by 2030 one in six people globally will be over 60, reaching 1.4 Billion people, with the over-80 population tripling to 426 Million by 2050, the demographic most susceptible to peptic ulcer disease, diverticular bleeding, and gastrointestinal malignancies requiring endoscopic hemostasis. More than 20 million gastrointestinal examinations are performed annually in the United States alone per the 2024 Scientific Reports meta-analysis, with endoscopic hemostasis required in a subset involving post-polypectomy bleeding, upper GI emergency bleeding presentations, and diagnostic biopsy sites. Boston Scientific reported Endoscopy segment revenues of USD 642 Million Q1 2024, USD 676 Million Q2 2024, and USD 678 Million Q3 2024 per SEC 8-K filings, confirming approximately USD 2.68 Billion FY2024 Endoscopy at 11% organic growth anchored in hemostatic clip and OverStitch procedure volume. These are some of the key factors driving revenue growth of the market.

The second driver is the commercial expansion of the topical hemostatic spray and powder category into hospital endoscopy unit device inventories, adding a fourth primary hemostasis modality alongside established mechanical clip, thermal coagulation, and injection therapy that addresses the specific clinical limitation of diffuse mucosal bleeding where clip placement is technically impractical and thermal coagulation risks mucosal injury across large surface areas. Topical hemostatic sprays work commercially because in patients with post-ESD resection defects of 3 centimetres or larger, diffuse post-polypectomy mucosal ooze, or coagulopathic GI bleeding conditions, spraying a hemostatic powder across the entire defect creates an immediate mechanical hemostatic matrix without requiring precise device placement under difficult endoscopic vision conditions, filling a clinical gap that the mechanical and thermal modalities leave unaddressed. Medtronic received US FDA clearance in September 2022 for Nexpowder, developed by NEXTBIOMEDICAL Korea, establishing a topical hemostatic powder spray for endoscopic use in gastrointestinal bleeding where diffuse mucosal bleeding or coagulopathic conditions make clipping or thermal coagulation technically challenging. NEXTBIOMEDICAL received MFDS approval from the Korean Ministry of Food and Drug Safety in November 2024 for Nexpowder-S, a next-generation formulation, and in July 2024 Medtronic launched an Advanced Energy Platform integrating AI algorithms for optimal energy delivery during thermal hemostasis, using real-time tissue impedance monitoring and automatic power adjustment. Cook Medical received CE marking in March 2024 for the Instinct Hemostatic Clip with innovative dual-arm design and enhanced radiopacity for improved visualisation during deployment. These are some of the key factors driving revenue growth of the market.

Boston Scientific Resolution Clip has impacted more than 2.5 million patient lives, establishing the largest hemostatic clip installed base and physician training network in global GI endoscopy. The commercial implication is that procedure urgency dynamics in emergency upper GI bleeding create intense GPO-anchored brand loyalty: when a patient presents with peptic ulcer bleeding, the endoscopist reaches for whichever clip is stocked in the endoscopy room, making brand switching a multi-year programme rather than a per-case clinical decision.

The third driver is the sustained investment in next-generation endoscopic hemostasis technology by the leading endoscopy platform companies, demonstrated by Olympus's EVIS X1 capability enhancements and USD 150 Million Innovation Ventures Fund II commitment, which together signal that the hemostasis device category is entering a technology enrichment phase where AI-guided energy delivery, bioabsorbable hemostatic materials, and multi-function combination devices will create new premium-priced device sub-categories above established clip and thermal coagulation offerings. Next-generation hemostasis devices work commercially because multifunctional devices combining clipping, coagulation, and injection capabilities in a single instrument reduce procedure complexity and time for endoscopists managing emergency bleeding presentations, while AI-integrated energy platforms that provide real-time tissue impedance feedback and automatic power adjustment reduce complication rates from over-treatment thermal injury that limits aggressive thermal hemostasis application at complex bleeding presentations. In May 2024, Olympus introduced the EVIS X1 endoscopy system with enhanced hemostasis capabilities incorporating narrow-band imaging and texture enhancement technologies to improve bleeding source identification at Asia Pacific and global clinical sites. In January 2024, CONMED acquired Biorez Inc., expanding its endoscopic hemostasis portfolio with bioabsorbable hemostatic materials and combination therapy devices. Olympus launched Innovation Ventures Fund II with an additional USD 150 Million in December 2025, reinforcing long-term hemostasis device innovation pipeline investment in endoscopy, diagnostics, and digital health. The effect on the market is that technology investment from both established device manufacturers and venture-funded startups is expanding the hemostasis device portfolio above the established mechanical clip, thermal coagulation, and injection therapy categories, creating incremental revenue opportunities in bioabsorbable clips, AI-guided energy platforms, and combination spray-plus-mechanical closure systems. These are some of the key factors driving revenue growth of the market.

However, the endoscopic hemostasis devices market faces adoption constraints from high device cost and technical complexity in lower-middle income countries and emerging market healthcare systems. Because purchase, maintenance, and logistics costs of endoscopy equipment remain a major barrier in LMICs per the 2024 ScienceDirect narrative review, with hemostatic clip per-unit costs of USD 200 to USD 600 per device substantially above injection epinephrine therapy costs of USD 5 to USD 20 per episode, facilities in budget-constrained settings default to injection monotherapy as the cost-effective first-line hemostasis approach, leaving the advanced mechanical and topical hemostasis categories commercially addressable only in private hospital and high-income healthcare system settings in these markets. Endoscopist workforce shortage is a second constraint, since safe hemostatic clip placement, argon plasma coagulation, and over-the-scope clip deployment require subspecialty gastroenterology training and procedural experience that many emerging market healthcare systems are still building, limiting emergency endoscopic hemostasis procedure volumes even where device access is available and creating a multi-decade physician training investment requirement before advanced hemostasis devices achieve broad procedure penetration in those markets. Reimbursement variability across device sub-categories is the third constraint, with established hemostatic clips and injection therapy devices having more uniform payer reimbursement frameworks than newer categories including topical hemostatic sprays, bioabsorbable clip materials, and AI-integrated energy platforms that are still completing clinical evidence dossiers and health technology assessment reviews in major payer markets. These factors substantially limit endoscopic hemostasis devices market growth over the forecast period.

Based on product, the global endoscopic hemostasis devices market is segmented into mechanical hemostasis devices including clips, band ligators, and loops, thermal devices including APC and bipolar probe systems, topical hemostatic agents, and injection therapy devices. Mechanical hemostasis devices hold the largest revenue share at approximately 38%, anchored by Boston Scientific Resolution Clip at 2.5 million patient lives, Olympus EZ Clip and QuickClip, and Cook Medical Instinct Hemostatic Clip, all generating recurring per-procedure device revenue from emergency GI bleeding management and prophylactic clipping at polypectomy sites. Topical hemostatic agents including sprays, powders, and gels are expected to register the most rapid revenue growth rate in the global endoscopic hemostasis devices market over the forecast period, driven by Medtronic Nexpowder FDA clearance September 2022 and Nexpowder-S MFDS approval November 2024 establishing a new clinical category for diffuse bleeding management.

Based on application, the global endoscopic hemostasis devices market is segmented into GI bleeding including upper GI peptic ulcer and variceal indications, lower GI bleeding including post-polypectomy and diverticular indications, bronchoscopic hemostasis, and urological and other endoscopic hemostasis. GI bleeding holds the largest revenue share, driven by the high annual incidence of emergency upper GI bleeding presentations requiring urgent endoscopic hemostasis at hospital gastroenterology services. Asia Pacific is expected to register the fastest revenue growth rate in the global endoscopic hemostasis devices market over the forecast period, driven by Japan's world-leading gastric cancer incidence requiring ESD procedures where prophylactic hemostatic clip placement and post-resection bleeding management are standard of care, and expanding access to advanced hemostasis technologies at Chinese and Indian tertiary hospital gastroenterology centres.

Based on regional analysis, the endoscopic hemostasis devices market in North America accounted for largest revenue share in 2025 at approximately 42% of global revenue. The United States drives the regional position through 240,000 or more annual GI bleeding events, Boston Scientific Endoscopy segment USD 2.68 Billion FY2024 US-anchored GPO contract positions, and an FDA-regulated product pipeline that positions US hospitals for first commercial access to new hemostasis device clearances. North American hospitals dominate adoption of advanced combination hemostasis systems including OverStitch endoscopic suturing for post-ESD defect closure and argon plasma coagulation for dysplasia and angiodysplasia management, supported by both the breadth of GPO contract coverage and the depth of ASGE-trained interventional endoscopist workforce at academic and community hospital gastroenterology departments.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, Italy, and the United Kingdom represent the four largest national hemostasis device markets within Europe. ERBE Elektromedizin, headquartered in Tubingen, Germany, is the leading European provider of argon plasma coagulation systems used for thermal hemostasis across upper and lower GI endoscopy procedures. Cook Medical CE marking of the Instinct Hemostatic Clip in March 2024 introduces enhanced radiopaque clip visualisation capability for European endoscopists managing complex GI bleeding presentations at difficult endoscopic locations. The Iran-US sanctions and associated Strait of Hormuz disruption do not directly affect endoscopic hemostasis device supply chains, as mechanical clip and thermal probe components are primarily manufactured in North American, Japanese, and European facilities outside the affected logistics corridors.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, South Korea, and India represent the four largest national hemostasis device markets within the region. Japan has the world's highest rate of gastric cancer and gastrointestinal polyposis requiring endoscopic mucosal resection and submucosal dissection procedures where hemostatic clip usage for defect closure and post-resection bleeding prevention is standard of care, and Olympus EVIS X1 enhanced hemostasis capabilities with narrow-band imaging and texture enhancement were unveiled in May 2024 targeting Asia Pacific clinical sites. China's expanding tertiary hospital gastroenterology centre infrastructure and India's growing GI cancer screening programme adoption are driving regional hemostasis device demand beyond the established Japan and South Korea installed base.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscopic hemostasis device markets. Brazil has a high prevalence of Helicobacter pylori infection contributing to peptic ulcer disease and upper GI bleeding events, with Medtronic Nexpowder providing a topical hemostasis option at Brazilian tertiary hospital gastroenterology units where post-ESD bleeding management is performed at private academic hospital endoscopy departments in Sao Paulo and Rio de Janeiro.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the GCC. GCC tertiary hospital gastroenterology departments managing variceal bleeding in patients with chronic liver disease and peptic ulcer bleeding in high-risk populations drive regional hemostasis device demand for band ligation, injection sclerotherapy, and clip-based mechanical hemostasis, with King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi operating among the most advanced therapeutic endoscopy programmes in the MEA region.